Paper Details

  1. Home
  2. Paper Details

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Author: , HauserThomas, JayneDavid R W, JonesRachel B, LuqmaniRaashid, MorganMatthew D, PehChen Au, SavageCaroline O, SegelmarkMårten, TervaertJan Willem Cohen, TesarVladimir, WalshDorothy, WalshMichael, WestmanKerstin, van PaassenPieter

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This article discusses the use of rituximab as a potential safer alternative to cyclophosphamide regimens for the treatment of refractory ANCA-associated vasculitis.
Paper Details　
Original Abstract of the Article :
Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa0909169

データ提供：米国国立医学図書館（NLM）

Rituximab Versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

This study compares the efficacy and safety of rituximab and cyclophosphamide in treating antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis, a potentially life-threatening autoimmune disease. The authors highlight the effectiveness of cyclophosphamide induction regimens but also note their associated high rates of death and adverse events. They present evidence that rituximab, a monoclonal antibody targeting B cells, can achieve comparable remission rates to cyclophosphamide, potentially offering a safer alternative for patients with ANCA-associated vasculitis.

Seeking Safer Treatment Options for ANCA-Associated Vasculitis

This study underscores the need for safer and more effective treatment options for ANCA-associated renal vasculitis, a potentially life-threatening condition. It's like finding a more sustainable path through a desert with limited resources - seeking alternative routes that minimize risks and maximize benefits. The findings suggest that rituximab could offer a valuable alternative to cyclophosphamide, potentially improving outcomes for patients with this challenging disease.

A Camel's Perspective on ANCA-Associated Vasculitis

As a camel, I understand the importance of navigating a desert with careful consideration of the potential risks and rewards. ANCA-associated vasculitis is a challenging condition, like encountering a sandstorm with limited visibility. This study provides valuable insights into potential treatment options, suggesting that rituximab could offer a safer and more effective approach to managing this disease.

Dr.Camel's Conclusion

Rituximab demonstrates comparable remission rates to cyclophosphamide in treating ANCA-associated renal vasculitis, potentially offering a safer treatment option with fewer adverse effects.
Date :
  1. Date Completed 2010-07-29
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

20647198

DOI: Digital Object Identifier

10.1056/NEJMoa0909169

Related Literature

Article Analysis
・Effective treatment of vasculitis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.